EULAR 2022 - New Data Show Durable Efficacy for Janssen’s TREMFYA Across Psoriatic Arthritis Domai

Returning guest Terence Rooney, M.D., Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC, discusses new data showing TREMFYA ® (guselkumab) provides durable efficacy through two years across the joint and axial symptoms of active psoriatic arthritis (PsA), regardless of patients’ baseline disease characteristics. TREMFYA patients also experienced sustained clinical improvements in measures of health-related quality of life, including pain and fatigue, through two years. These data were presented at the European Alliance of Associations for Rheumatology (EULAR) annual meeting 2022 in Copenhagen.

#PsoriaticArthritis

Terence Rooney, M.D., is Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology and maternal-fetal disease area, overseeing innovative compounds across multiple phases of development. Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development.